MET and glioblastoma: Another independent study by Chi and colleagues showed a rapid and efficient clinical and radiographic response when a GBM patient with confirmed MET-amplified status was treated with crizotinib (PF-02341066), a dual ATP competitive inhibitor of Met (cellular IC50, 8 nM) and anaplastic lymphoma kinase (ALK) (cellular IC50, 20 nM) [69].